Terms: = Uterine cancer AND CTNNB1, P35222, 1499, ENSG00000168036, CTNNB AND Prognosis
29 results:
1. HER2+ endometrioid endometrial cancer possesses distinct molecular and immunologic features associated with a more active immune microenvironment and worse prognosis.
Bruce SF; Wu S; Ribeiro JR; Farrell A; Oberley MJ; Winer I; Erickson BK; Klc T; Jones NL; Thaker PH; Powell MA
Gynecol Oncol; 2023 May; 172():98-105. PubMed ID: 37003074
[TBL] [Abstract] [Full Text] [Related]
2. Diagnostic accuracy of mutational analysis along the Müllerian tract to detect ovarian cancer.
van Bommel MHD; Pijnenborg JMA; van der Putten LJM; Bulten J; Snijders MPLM; Küsters-Vandevelde HVN; Sweegers S; Vos MC; Ligtenberg MJL; Eijkelenboom A; de Hullu JA; Reijnen C
Int J Gynecol Cancer; 2022 Dec; 32(12):1568-1575. PubMed ID: 36384753
[TBL] [Abstract] [Full Text] [Related]
3. Molecular Evidence for Epithelial Origin of Mixed Ovarian Epithelial-Germ Cell Neoplasms: Report of 2 Cases and Review of Literature.
Hall KC; Post MD; Alldredge J; Aisner DL; Berning A
Int J Gynecol Pathol; 2023 Jul; 42(4):403-413. PubMed ID: 36305517
[TBL] [Abstract] [Full Text] [Related]
4. Clinical impact of genetic alterations of ctnnb1 in patients with grade 3 endometrial endometrioid carcinoma.
Kobayashi Kato M; Asami Y; Takayanagi D; Matsuda M; Shimada Y; Hiranuma K; Kuno I; Komatsu M; Hamamoto R; Matsumoto K; Ishikawa M; Kohno T; Kato T; Shiraishi K; Yoshida H
Cancer Sci; 2022 May; 113(5):1712-1721. PubMed ID: 35278272
[TBL] [Abstract] [Full Text] [Related]
5. Clinicopathologic Evaluation and Molecular Profiling of Recurrent Stage IA Endometrial Endometrioid Carcinoma: A Case-control Study.
Sharma AE; Moran A; Somasegar S; Steinhardt G; Chapel DB; Lastra RR; Lee NK; Ritterhouse LL; Bennett JA
Int J Gynecol Pathol; 2023 Jan; 42(1):26-34. PubMed ID: 35125405
[TBL] [Abstract] [Full Text] [Related]
6. Clinicopathological features and prognostic significance of ctnnb1 mutation in low-grade, early-stage endometrial endometrioid carcinoma.
Ruz-Caracuel I; López-Janeiro Á; Heredia-Soto V; Ramón-Patino JL; Yébenes L; Berjón A; Hernández A; Gallego A; Ruiz P; Redondo A; Peláez-García A; Mendiola M; Hardisson D
Virchows Arch; 2021 Dec; 479(6):1167-1176. PubMed ID: 34420090
[TBL] [Abstract] [Full Text] [Related]
7. Molecularly Classified uterine FIGO Grade 3 Endometrioid Carcinomas Show Distinctive Clinical Outcomes But Overlapping Morphologic Features.
Joehlin-Price A; Van Ziffle J; Hills NK; Ladwig N; Rabban JT; Garg K
Am J Surg Pathol; 2021 Mar; 45(3):421-429. PubMed ID: 33021522
[TBL] [Abstract] [Full Text] [Related]
8. ctnnb1 Mutations and Aberrant β-Catenin Expression in Ovarian Endometrioid Carcinoma: Correlation With Patient Outcome.
Zyla RE; Olkhov-Mitsel E; Amemiya Y; Bassiouny D; Seth A; Djordjevic B; Nofech-Mozes S; Parra-Herran C
Am J Surg Pathol; 2021 Jan; 45(1):68-76. PubMed ID: 32769429
[TBL] [Abstract] [Full Text] [Related]
9. Clinical patterns and genomic profiling of recurrent 'ultra-low risk' endometrial cancer.
Stasenko M; Feit N; Lee SSK; Shepherd C; Soslow RA; Cadoo KA; Alektiar K; Da Silva EM; Martins Sebastião AP; Leitao MM; Gardner G; Selenica P; Abu-Rustum NR; Weigelt B; Mueller JJ
Int J Gynecol Cancer; 2020 Jun; 30(6):717-723. PubMed ID: 32376737
[TBL] [Abstract] [Full Text] [Related]
10. Identification of a Gene Panel for Endometrioid Endometrial cancer: a Possible Prognostic Value?
Malentacchi F; Turrini I; Sorbi F; Projetto E; Castiglione F; Vergoni F; Amunni G; Fambrini M; Petraglia F; Noci I; Pillozzi S
Reprod Sci; 2020 Feb; 27(2):592-598. PubMed ID: 32046431
[TBL] [Abstract] [Full Text] [Related]
11. The relationship between
Çintesun FNİ; Kerimoğlu ÖS; Çintesun E; Nergiz S; Acar H; Çelik Ç
J Obstet Gynaecol; 2020 Oct; 40(7):988-993. PubMed ID: 31790621
[TBL] [Abstract] [Full Text] [Related]
12. Early-stage endometrial cancer, ctnnb1 mutations, and the relation between lymphovascular space invasion and recurrence.
Imboden S; Tapia C; Scheiwiller N; Kocbek V; Altermatt HJ; Janzen J; Mueller MD; McKinnon B
Acta Obstet Gynecol Scand; 2020 Feb; 99(2):196-203. PubMed ID: 31562818
[TBL] [Abstract] [Full Text] [Related]
13. Whole Genome Analysis and Prognostic Model Construction Based on Alternative Splicing Events in Endometrial cancer.
Wang C; Zheng M; Wang S; Nie X; Guo Q; Gao L; Li X; Qi Y; Liu J; Lin B
Biomed Res Int; 2019; 2019():2686875. PubMed ID: 31355251
[TBL] [Abstract] [Full Text] [Related]
14. Immunohistochemical Nuclear Expression of β-Catenin as a Surrogate of ctnnb1 Exon 3 Mutation in Endometrial cancer.
Travaglino A; Raffone A; Saccone G; De Luca C; Mollo A; Mascolo M; De Placido G; Insabato L; Zullo F
Am J Clin Pathol; 2019 Apr; 151(5):529-538. PubMed ID: 30715091
[TBL] [Abstract] [Full Text] [Related]
15. Multiclonality and Marked Branched Evolution of Low-Grade Endometrioid Endometrial Carcinoma.
Lazo de la Vega L; Samaha MC; Hu K; Bick NR; Siddiqui J; Hovelson DH; Liu CJ; Carter CS; Cho KR; Sciallis AP; Tomlins SA
Mol Cancer Res; 2019 Mar; 17(3):731-740. PubMed ID: 30610106
[TBL] [Abstract] [Full Text] [Related]
16. Genomic characterization of cervical cancer based on human papillomavirus status.
Zhang L; Jiang Y; Lu X; Zhao H; Chen C; Wang Y; Hu W; Zhu Y; Yan H; Yan F
Gynecol Oncol; 2019 Mar; 152(3):629-637. PubMed ID: 30581036
[TBL] [Abstract] [Full Text] [Related]
17. High frequency of POLE mutations in synchronous endometrial and ovarian carcinoma.
Ishikawa M; Nakayama K; Nakamura K; Ono R; Yamashita H; Ishibashi T; Minamoto T; Iida K; Razia S; Ishikawa N; Kyo S
Hum Pathol; 2019 Mar; 85():92-100. PubMed ID: 30448219
[TBL] [Abstract] [Full Text] [Related]
18. Nuclear β-catenin and CDX2 expression in ovarian endometrioid carcinoma identify patients with favourable outcome.
Wang L; Rambau PF; Kelemen LE; Anglesio MS; Leung S; Talhouk A; Köbel M
Histopathology; 2019 Feb; 74(3):452-462. PubMed ID: 30326146
[TBL] [Abstract] [Full Text] [Related]
19. Genetic Investigation of uterine Carcinosarcoma: Case Report and Cohort Analysis.
Hembree TN; Teer JK; Hakam A; Chiappori AA
Cancer Control; 2016 Jan; 23(1):61-6. PubMed ID: 27009459
[TBL] [Abstract] [Full Text] [Related]
20. Refining prognosis and identifying targetable pathways for high-risk endometrial cancer; a TransPORTEC initiative.
Stelloo E; Bosse T; Nout RA; MacKay HJ; Church DN; Nijman HW; Leary A; Edmondson RJ; Powell ME; Crosbie EJ; Kitchener HC; Mileshkin L; Pollock PM; Smit VT; Creutzberg CL
Mod Pathol; 2015 Jun; 28(6):836-44. PubMed ID: 25720322
[TBL] [Abstract] [Full Text] [Related]
[Next]
